This is a Validated Antibody Database (VAD) review about rhesus mac.. PTA1, based on 8 published articles (read how Labome selects the articles), using PTA1 antibody in all methods. It is aimed to help Labome visitors find the most suited PTA1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
PTA1 synonym: PTA1

BioLegend
mouse monoclonal (11A8)
  • blocking or activating experiments; human; 10 ug/ml; loading ...; fig 2e
BioLegend PTA1 antibody (Biolegend, 11A8) was used in blocking or activating experiments on human samples at 10 ug/ml (fig 2e). BMC Biol (2021) ncbi
mouse monoclonal (11A8)
  • other; mouse
BioLegend PTA1 antibody (BioLegend, 11A8) was used in other on mouse samples . Nat Commun (2020) ncbi
mouse monoclonal (11A8)
  • flow cytometry; human; loading ...
BioLegend PTA1 antibody (BioLegend, 11A8) was used in flow cytometry on human samples . elife (2020) ncbi
mouse monoclonal (11A8)
  • flow cytometry; human; loading ...
BioLegend PTA1 antibody (Biolegend, 11A8) was used in flow cytometry on human samples . Front Immunol (2019) ncbi
mouse monoclonal (11A8)
  • flow cytometry; human; loading ...; fig s2
BioLegend PTA1 antibody (BioLegend, 338312) was used in flow cytometry on human samples (fig s2). BMC Cancer (2019) ncbi
mouse monoclonal (11A8)
  • flow cytometry; human; loading ...; fig 2a
BioLegend PTA1 antibody (Biolegend, 11A8) was used in flow cytometry on human samples (fig 2a). Front Immunol (2019) ncbi
mouse monoclonal (11A8)
  • flow cytometry; human; loading ...; fig s5a
In order to detail MAIT cell responses to various microorganisms and cytokines, BioLegend PTA1 antibody (BioLegend, 11A8) was used in flow cytometry on human samples (fig s5a). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (11A8)
  • flow cytometry; human; fig 7
In order to study the functions of WASp knock out natural killer cells, BioLegend PTA1 antibody (Biolegend, 338304) was used in flow cytometry on human samples (fig 7). Sci Rep (2016) ncbi
Articles Reviewed
  1. Zhu Y, Xie J, Shi J. Rac1/ROCK-driven membrane dynamics promote natural killer cell cytotoxicity via granzyme-induced necroptosis. BMC Biol. 2021;19:140 pubmed publisher
  2. Tseng H, Xiong W, Badeti S, Yang Y, Ma M, Liu T, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11:4810 pubmed publisher
  3. Hood S, Cosma G, Foulds G, Johnson C, Reeder S, McArdle S, et al. Identifying prostate cancer and its clinical risk in asymptomatic men using machine learning of high dimensional peripheral blood flow cytometric natural killer cell subset phenotyping data. elife. 2020;9: pubmed publisher
  4. Sanz Ortega L, Rojas J, Portilla Y, Pérez Yagüe S, Barber D. Magnetic Nanoparticles Attached to the NK Cell Surface for Tumor Targeting in Adoptive Transfer Therapies Does Not Affect Cellular Effector Functions. Front Immunol. 2019;10:2073 pubmed publisher
  5. Choi J, Lee E, Kim S, Park S, Oh S, Kang J, et al. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer. BMC Cancer. 2019;19:817 pubmed publisher
  6. Ingegnere T, Mariotti F, Pelosi A, Quintarelli C, De Angelis B, Tumino N, et al. Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing. Front Immunol. 2019;10:957 pubmed publisher
  7. Dias J, Leeansyah E, Sandberg J. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc Natl Acad Sci U S A. 2017;114:E5434-E5443 pubmed publisher
  8. Kritikou J, Dahlberg C, Baptista M, Wagner A, Banerjee P, Gwalani L, et al. IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo. Sci Rep. 2016;6:30636 pubmed publisher